always on

Yuval Horn, Assaf Unger and Ben Baharav represented INX Limited in the sale transaction of INX’s wholly owned subsidiary, I.L.S. Brokers Ltd., to a UK-based global financial services firm.

September 3, 2024

Horn & Co. contributed the Israeli chapter of the Thomson Reuters security considerations practice note.

June 11, 2024

Keren Kanir & Roy Ribon advised Savoreat Ltd. in a manufacturing agreement with a well known and veteran American manufacturer.

June 10, 2024

Shimrit Roznek moderated a panel about M&A in Life Sciences at the IBA WLSC Conference held in Madrid on May 29-30, 2024.

May 13, 2024

Yuval Horn co-chaired the IBA 10th World Life Sciences Conference to be held in Madrid on 29 -31 May, 2024.

May 12, 2024

Yuval Horn and Keren Kanir represented AIgnostics GMBH in a strategic collaboration agreement with Bayer.

March 14, 2024

Yuval Horn Co-chaired the International Bar Association 7th M&A in the Tech Sector Conference in Barcelona.

March 14, 2024

Yuval Horn, Shimrit Roznek and Yael Bar Hillel represented Metabomed Ltd. in its Asset Purchase Agreement with EpiVario Inc., for the sale of Metabomed’s small molecule acetyl co-A synthetase-2 inhibitor portfolio.

January 24, 2024

Yuval Horn, Yonatan Levinstein & Tal Gazanda represented Prisma Photonics in the Series C Investment agreement with IEC.

December 20, 2023

Despite the times, Yuval Horn Co-moderated a panel about #AI and Medical Devices at the #IBA Annual Conference in Paris.

November 2, 2023

Congratulations to our client, Biosight Ltd. on completing the merger with Ayala Pharmaceuticals, Inc. Yuval Horn, Assaf Unger and Ana Eiskov represented Biosight, together with Mayan Katz of Goodwin.

October 22, 2023

Congratulations to our client, Vascular Biogenics Ltd. (Nasdaq: VBLT) on completing the merger with Notable Labs and the sale of its IP assets. VBL was represented by Horn & Co. (Yuval Horn, Shimrit Roznek, Roy Ribon, Yael Bar-Hillel and Shai Perel) and by Goodwin.

October 19, 2023

Yuval Horn, Assaf Unger, Ana Eiskov and Shiran Glantz represent Biosight Ltd. in the merger agreement with Ayala Pharmaceuticals, Inc.

July 31, 2023

Yuval Horn, Assaf Unger, Ana Eiskov and Revital Guttman represented our client, INX, in its investment and collaboration transactions with Republic

June 25, 2023

Yuval Horn Co-chaired the IBA 9th Annual World Life Sciences Conference in Washington.

June 2, 2023

Keren Kanir, Yuval Horn and Danielle Wassner represented Scopio Labs in its collaboration agreement with Siemens Healthineers to Distribute Full-Field Digital Cell Morphology Technology

May 10, 2023

Uri Dotan and Shira Brami represented Vidac Pharma Ltd. in the registration of Its securities on the Hamburg Stock Exchange

April 5, 2023

Yuval Horn Co Chaired the IBA 6th M&A in the Tech Sector Conference on March 23-24, 2023.

March 25, 2023

Tal Gazanda represented ART MEDICAL in a strategic collaboration agreement with Teva Pharmaceuticals (TEVA).

March 19, 2023

Yuval Horn, Paz Abercohen, Ana Eiskov, Shiran Glantz and Shai Perel represent VBL in the merger with Notable.

February 23, 2023

Yuval Horn, Shimrit Roznek, Yael Bar Hillel and Taisia Kris represent VBL in the Agreement to Sell the Manufacturing Facility and Certain Related Assets for $7.1 Million.

February 23, 2023

Yuval Horn, Keren Kanir, Yonatan Levinstein and Dorin Cohn Arbel represented Immunorizon on the acquisition by Purple Biotech (NASDAQ/TASE: PPBT) in consideration for up to $100 million.

February 6, 2023

Shimrit Roznek Co-Chaired the IBA 5th Silicon Beach Conference on January 21-24, 2023

January 25, 2023

Yuval Horn, Assaf Unger and Ana Eiskov represented The INX Digital Company, Inc. in a joint venture with SICPA SA in the field of central bank digital currencies.

December 22, 2022

Uri Dotan and Shiran Glantz represent Pangea in its seed investment round

December 16, 2022

Yuval Horn & Shimrit Roznek represented Kamari Pharma in a Joint Venture Agreement raising 8 Million USD.

September 19, 2022

Yuval Horn, Yonatan Levinstein and Tal Gazanda represented Prisma Photonics in a strategic investment agreement with Israel Natural Gas Lines (INGL). Mazal tov to Eran Inbar and the team on this great vote of confidence!

August 2, 2022

Yuval Horn, Keren Kanir and Yonatan Levinstein represented Diagnostic Robotics in its Series B fundraising round lead by StageOne Ventures with participation by Mayo Clinic Ventures

July 26, 2022

Keren Kanir and Dorin Cohn Arbel advised Scopio Labs on its new and exciting distribution partnership with Beckman Coulter Diagnostics.

July 22, 2022

Uri Dotan and Shiran Glantz represented Nanosynex Ltd. In the control acquisition transaction with Qualigen Therapeutics, Inc. (NASDAQ:QLGN)

June 2, 2022

Yuval Horn, Yonatan Levinstein and Tal Gazanda represented Prisma Photonics Ltd. in its $20 million raise from Insight Partners, Schneider Electric and Future Energy Ventures.

February 10, 2022

Horn & Co. Law Office welcomes its new partners – January 2022

January 16, 2022

Yuval Horn, Assaf Unger and Ana Eiskov of Horn & Co. represented INX Limited in its merger and $35 million fundraising.

January 10, 2022

Adv. Yonatan Levinstein represented Prisma Photonics in an agreement with the New York Power Authority (NYPA), the largest state public utility in the U.S.. Prisma’s groundbreaking technology will use optical fiber sensing and artificial intelligence to detect potentially disruptive activity on NYPA transmission lines

December 27, 2021

Adv. Yuval Horn, Yonatan Levinstein and Yael Bar Hillel advised Pontifax Ventures 6, which lead an 87 million Euro investment in Emergence Therapeutics. Horn & Co was assisted by Gleiss Lutz.

December 23, 2021

Pontifax Venture Capital and Kreos Capital provided 10 million EUR debt financing to Oxurion NV. Yonatan Levinstein of Horn & Co., Law Offices represented Pontifax Ventures.

November 24, 2021

Prisma Photonics Ltd., a provider of next-generation fiber sensing for smart infrastructure, entered into a partnership with Schneider Electric., a leader in the digitization of energy management and automation. Yonatan Levinstein and Danielle Wassner represented Prisma Photonics. Nov 17, 2021

November 17, 2021

 Nanox AI, known, since incorporation, as Zebra Medical Vision Ltd, completed the merger with Nanox Vision. Thanks to Yuval Horn, Uri Dotan and Shiran Glantz of Horn & Co., Law Offices for their tireless efforts

November 8, 2021

“Entrepreneurship in the Life Sciences – Legal and Practical Aspects”- course by Yuval Horn-open for registration!

August 13, 2021

Zebra Medical Vision Ltd. executes $200 million merger agreement with Nanox Vision Ltd. Yuval Horn, Uri Dotan and Shiran Glantz represented Zebra

August 11, 2021

Keren Kanir and Yuval Horn of Horn & Co., Law Offices advised Theator in the collaboration with Mayo Clinic

July 22, 2021

Yuval Horn, Assaf Unger and Ana Eiskov represented Biosight Ltd. in the merger agreement with Advaxis

July 6, 2021

Keren Kanir, Yuval Horn and Ofer Inbar represented INX Limited in the acquisition of ILS Brokers

June 15, 2021

Yuval Horn, Orly Sternfeld and Tal Gazanda of Horn & Co., Law Offices represented Voodoo.io in the acquisition of BidShake

June 10, 2021

Our firm represented Panaxia in an asset purchase agreement

May 31, 2021

Yuval Horn, Assaf Unger and Ana Eiskov represented INX in the merger and $39.6 million CAD financing

April 2, 2021

Cellect Biotechnology and Quoin Pharmaceuticals Announce Strategic Merger

March 24, 2021

The International Bar Association M&A in the Tech Sector conference

March 22, 2021

We represented Biosight in Closing Financing to Advance Clinical Oncology Programs

December 3, 2020

Horn & Co. represented “Savoreat” in the first Food-tech IPO

November 26, 2020

IBA2020 Conference “VirtuallyTogether” will be held on November 18, 2020

November 15, 2020

Congrats to the entire INX Limited team, who made history today by announcing the effectiveness of Security Token IPO

August 26, 2020

Another important milestone for Zebra Medical Vision Ltd- innovative partnership for AI implementation with Canon USA

August 12, 2020

Horn & Co. represented Pontifax’s Venture Lending Fund in a $30M Convertible Debt Financing Agreement with ProQR Therapeutics N.V

July 15, 2020

Proud to be ranked, again, by IAM Magazine as one of top 4“highly recommended” Israeli firms in intellectual property transactions

June 14, 2020

Vascular Biogenics Ltd. raises an additional $8.1 million, completing an aggregate $18.1 million raise. Yuval Horn, Keren Kanir and Shimrit Roznek represented VBL in this transaction.

May 13, 2020

Horn & Co. has been recognized by Legal 500 as a “Tier 1” firm in Israel in the field of Healthcare and Life Sciences

May 4, 2020

Proud of our client, Diagnostic Robotics Ltd. that developed a system for detecting COVID-19

March 30, 2020

Yuval Horn noted once again as a Thought Leader Global Elite 2020 in Life Sciences by Who’s Who Legal, the only individual from Israel

February 20, 2020

“They were providing services to one of the more innovative projects coming out of Israel in blockchain and trying to secure SEC approval for a project, which is very difficult to get.”

January 21, 2020

Paz Abercohen, Yuval Horn and Yonatan Levinstein of Horn & Co. represented Raziel Therapeutics in its $22 million series C round, led by Pontifax, with participation from existing investors as well as new investors, Catalyst Fund, Quark venture, Peregrine Investments and Wille AG.

December 18, 2019

International Divorce Conference

November 25, 2019

Yuval Horn will moderate a panel about AI and eHealth disruption in the medical and lifestyle markets with Markus von Fuchs at the upcoming IBA 6th Biennial Technology Law Conference in Berlin.

October 10, 2019

Yuval Horn moderated a panel with Rabel Z. Akhund on the regulation of crypto trading platforms.

September 25, 2019

Yuval Horn moderated, with Doil Son of Yulchon (Seoul) a panel on Data in M&A at the Annual Meeting of the International Bar Association in Seoul.

September 24, 2019

Paz Abercohen of Horn & Co. represented Biolight Life Sciences Ltd. in its investment in Sanoculis Ltd., a medical device company which develops an innovative surgical procedure for treatment of Glaucoma

September 15, 2019

Proud to be ranked, again, by IAM Magazine (Intellectual Asset Management) as one of top 5 “highly recommended” Israeli firms in intellectual property transactions

July 1, 2019

Cyber Incident Response and Data Breach Notification

May 1, 2019

Information security consideration (Israel)

May 1, 2019

Horn & Co. has been recognized by Legal 500 as a “Tier 1” firm in Israel in the field of Healthcare and Life Sciences. Yuval Horn was noted as a Tier I practitioner. Legal 500 notes: “Horn & Co is known for providing top-quality service, particularly to pharmaceutical companies and investors, in relation to IP, commercial agreements, M&A and regulatory matters.” The firm was further recognized as a leading firm in the fields of Hi-tech and start-ups and IP transactions.

April 1, 2019

Horn & Co. once again recognized as one of the elite law firms in Israel by Dun & Bradstreet, in its 2018 ranking by fields of expertise.

March 1, 2019

Yuval Horn, Ohad Mamann and Anat Polyachenko of Horn & Co. represented the shareholders of Famewave Ltd. in the acquisition of Famewave by Kitov Pharmaceuticals Ltd.  (NASDAQ/TASE: KTOV) in consideration for $10 million and a simultaneous investment of $3.5 million by certain shareholders in Kitov. Famewave Ltd. was set up by the former shareholders of cCAM Biotherapeutics Ltd., which we represented in the acquisition by MSD in 2015.

March 1, 2019

Yuval Horn will co-chair the 4th Annual Mergers and Acquisitions in the Technology Sector Conference of the International Bar Association, to take place on March 28-29, 2019 in Barcelona.

February 1, 2019

Proud of our partner, Keren Kanir, who was included in the impressive list of the leading female lawyers in Israel, naming her as a notable Israeli practitioner in corporate-biotech.

November 1, 2018

Horn & Co. was recognized by Chambers and Partners as a leading firm in FinTech stating: “They are best known within FinTech for their work on blockchain and tokenisation, with a number of cutting-edge and highly respected mandates in the area.” Yuval Horn was ranked as a leading individual stating: ‘Clients describe Horn as a “smart, efficient and professional” lawyer who is “doing excellent work on ICOs.”’.

November 1, 2018

Yuval Horn noted as the sole Israeli expert in the Finance and Transactional Expert listing of the Expert Guides: Life Sciences. The experts are chosen by senior practitioners or in house counsel involved in each practice area in over 80 jurisdictions.

November 1, 2018

The LPD Showcase: initial coin offerings (ICOs) – technology meets finance

October 1, 2018

Shaking Up the Status Quo published on October 9, 2018 (IBA)

October 1, 2018

Congratulations to our client, IOPtima Ltd., on the completion of the second stage of its acquisition transaction with Chengdu Kanghong Pharma Group Co. Ltd. Horn & Co. team was led by Yuval Horn, Paz Abercohen and Uri Dotan.

September 28, 2018

Yuval Horn participates in theIBA 4th Mergers and Acquisitions in the Technology Sector Conference

September 17, 2018

Horn & Co. represented Spacemesh in a Series A $15M financing round led by Polychain Ventures, with participation from the world’s leading blockchain oriented investment funds. The Horn & Co. team was led by Yuval Horn, Ohad Mamann and Maya Weiss Donin. Tomer Afek, Aviv Eyal and Ifat Linur – congratulations on this impressive milestone!

September 6, 2018

Congratulations to our client, IOPtima Ltd., on the completion of the second stage of its acquisition transaction with Chengdu Kanghong Pharma Group Co. Ltd. Horn & Co. team was led by Yuval Horn, Paz Abercohen and Uri Dotan.

September 1, 2018

Proud to lead the list of top Israeli firms specializing in Hi-tech with an equal number of female and male partners, as described in this interesting article by @themarker.

August 8, 2018

Yuval Horn and Keren Kanir of Horn & Co. represented Anima Biotech in an exclusive collaboration agreement with Eli Lilly, with a total deal value exceeding $1 billion.

July 24, 2018

Proud to be ranked, again, by IAM Magazine (Intellectual Asset Management) as one of top 4 “highly recommended” Israeli firms in intellectual property transactions: “Horn & Co’s small size belies the reputation it enjoys with regard to the commercialisation of intellectual property.

June 10, 2018

Congratulations to our client, Zebra Medical for closing an impressive $30M financing round led by aMoon Ventures, with participation from Aurum, Johnson & Johnson Innovation and additional new and current investors.

June 10, 2018

Yuval Horn chosen as “Thought Leader” of Life Sciences Transactions by Who’s Who Legal: Life Sciences 2018.

May 13, 2018

Horn & Co. has been recognized again by Legal 500 as a “Tier 1” firm in Israel in the field of Healthcare and Life Sciences.

April 15, 2018

Yuval Horn and Ohad Mamann of Horn & Co. represented Pontifax, who led  a €16 million Series A round and restructuring in ABAC Therapeutics, Inc.

February 27, 2018

Who’s who legal – Data, Data, Data

February 1, 2018

An article (Hebrew) written by @Yuval Horn, @Roy Ribon and @Assaf Unger of Horn & Co., with respect to legal aspects of blockchain assets and cryptocurrency offerings, published on @themarker.

January 29, 2018

Yuval Horn, Paz Abercohen and Uri Dotan of Horn & Co. represented IOptima Ltd. and its shareholders, including Biolight Life Sciences Investments Ltd (TASE: BOLT) in a multi-stage acquisition transaction with an aggregate deal value of up to approximately $50 million, with Chengdu Kanghong Pharmaceutical Group, a Chinese life sciences company listed on the Shenzhen stock exchange.

November 28, 2017

Yuval Horn, Keren Kanir and Uri Dotan of Horn & Co. represented Vascular Biogenics Ltd. (Nasdaq: VBLT) in its $18.75 Million follow-on offering on NASDAQ.

November 26, 2017

Yuval Horn and Paz Abercohen of Horn & Co. acted as Israeli counsel to Protalix BioTherapeutics, Inc. (NYSE: PLX) in a $9 Million private notes exchange agreement, and a $10 Million private placement of the company’s Secured Convertible Notes.

July 27, 2017

Horn & Co. ranked, again, by iam Magazine (Intellectual Asset Management) as one of top 3 “highly recommended” Israeli firms in the field of intellectual property transactions

June 13, 2017

Yuval Horn, Keren Kanir, Ohad Mamann and Tammy Alon of Horn & Co., Law Offices represented Eloxx Pharmaceuticals Ltd. in its Series C financing round and simultaneous entering into an agreement for an acquisition transaction with Sevion Therapeutics, Inc.

June 4, 2017

Adv. Yuval Horn participated in the 5th Annual World Life Sciences Conference

June 1, 2017

Horn & Co. has been recognized by Legal 500 as a “Tier 1” firm in Israel in the field of Healthcare and Life Sciences. Yuval Horn was noted as a Tier I practitioner. Legal 500 notes: “the firm has been active at the ‘top level’ in the healthcare sector for over 20 years”

April 23, 2017

Yuval Horn, Roy Ribon and Yasmin Zohar of Horn & Co. acted as Israeli counsel to Therapix Biosciences Ltd. (NASDAQ: TRPX) (TASE: THXBY), in its listing on Nasdaq and offering of $12 million

March 23, 2017

Horn & Co. once again recognized as one of the elite law firms in Israel by Dun & Bradstreet, in its 2017 ranking by fields of expertise

March 17, 2017

Adv. Yuval Horn participated in the 3rd Silicon Beach Conference All Along the Spectrum – From Start-Up to IPO/Exit and Beyond

February 1, 2017

Yuval Horn was noted as one of leading practitioners in Israel in the field of Information Technology by the 2017 edition of Who’s Who Legal: Telecommunications Media & Technology

January 11, 2017

Adv. Paz Abercohen joined the firm as a partner

January 10, 2017

Yuval Horn and Ohad Mamann of Horn & Co. represented the investors in ArtsAvit’s financing round, led by Pontifax, Arkin Holdings and Merck Ventures

January 5, 2017

Vascular Biogenics Ltd. (NASDAQ:VBLT) Announces $24 Million Registered Direct Offering

December 18, 2016

Yuval Horn and Paz Abercohen of Horn & Co. acted as Israeli counsel to Protalix BioTherapeutics, Inc. (NYSE: PLX) in a $54.1 Million private notes exchange agreement, and a $22.5 Million private placement of the company’s Secured Convertible Notes

December 8, 2016

IBA 2nd M&A conference in the technology sector crowned with success

October 30, 2016

Yuval Horn, Keren Kanir and Uri Dotan of Horn & Co. represented Vascular Biogenics Ltd. in its $24 Million follow-on offering on NASDAQ

June 20, 2016

Yuval Horn participates in the WHO’S WHO LEGAL’S ROUNDTABLE: LIFE SCIENCES 2016

June 20, 2016

Horn & Co. listed by iam Magazine as one of top 3 “highly recommended” Israeli firms in the field of intellectual property transactions

May 31, 2016

Yuval Horn and Orly Sternfeld of Horn & Co. represented Zebra Medical Vision Ltd. in its Series B financing round

May 25, 2016

Yuval Horn and Orly Sternfeld of Horn & Co. represented Zebra Medical Vision Ltd. in its Series B financing round led by Intermountain Healthcare

May 25, 2016

Yuval Horn and Keren Margalit of Horn & Co. represented BioSight Ltd. in its Series B financing round led by Arkin Holdings and US based venture firm Primera Capital

May 18, 2016

Yuval Horn to moderate the corporate finance panel at the IBA 4th Annual World Life Sciences Conference on July 3, 2016 in San Francisco

May 4, 2016

Yuval Horn and Ohad Mamann of Horn & Co. represented the lead investors in cancer metabolism start-up Metabomed’s series A financing round

April 21, 2016

Yuval Horn will co-chair the 2nd Annual Mergers and Acquisitions in the Technology Sector Conference of the International Bar Association, to take place on October 27-28, 2016 in Tel Aviv

April 7, 2016

Adv. Orly Sternfeld joined the firm as a partner

January 17, 2016

Yuval Horn to participate in an Executive Briefing about: Risks and Rewards of Expanding into the United States, on January 31, 2016

January 12, 2016

Yuval Horn and Orly Sternfeld of Horn & Co. advised Zebra Medical Vision Ltd. in its collaboration agreement with Dell Services to enable next-generation clinical insights and better population health management

November 25, 2015

Yuval Horn, Keren Kanir and Uri Dotan of Horn & Co. represented Vascular Biogenics Ltd. in its $15 Million follow-on offering on NASDAQ

November 3, 2015

Yuval Horn was announced as the incoming Co-Chair of the International Bar Association Technology Law Committee

October 19, 2015

Yuval Horn to moderate a panel relating to Regulation of Genetic Testing at the IBA Annual Conference in Vienna in October, 2015

September 2, 2015

Horn & Co. represented cCam Biotherapeutics Ltd. and its shareholders in the acquisition by Merck Sharp & Dohme for $605 million.

July 28, 2015

Taboola.com increases its $117 million private financing round, and closes follow-on investments with Baidu Inc. and DailyMail.com.

June 21, 2015

Horn & Co. listed by iam Magazine (Intellectual Asset Management) as one of the top 6 recommended Israeli firms in the field of Licensing.

June 18, 2015

Adv. Yuval Horn participated in the 3rd Annual IBA World Life Sciences Conference

June 1, 2015

Biolight Israeli Life Sciences Investments Ltd (TASE: BOLT) executes memorandum for strategic cooperation in China and closes $6.2 million investment with investors based in Hong Kong.

May 12, 2015

Angioslide Ltd. closes a strategic license agreement for the Asian market and round D investment round with a consortium of Chinese investors.

May 10, 2015

Polyheal Ltd. enters into a manufacturing and distribution license agreement with Praxis Pharmaceutical S.A.

May 3, 2015

Intec Pharma Ltd. enters into a Research, Option and Licensing Agreement with one of the world’s top 20 pharmaceutical companies, in terms of market cap.

April 26, 2015

Yuval Horn noted as one of 5 most highly regarded practitioners worldwide in life sciences transactions

March 16, 2015

Yuval Horn will co chair the keynote and corporate finance panels at the upcoming IBA World Life Sciences Conference on June 12 in Philadephia

March 12, 2015

Cellera, Inc. closes asset purchase agreement for undisclosed amount

March 12, 2015

Taboola.com closes $117 million private financing round

February 4, 2015

Adv. Roy Ribon and Adv. Ohad Mamann joined the firm as partners

January 13, 2015

Yuval Horn nominated Vice Chairman of the International Bar Association Technology Law Committee.

December 21, 2014

Medivation Inc. (represented by Horn & Co.) Licenses Clinical Stage Anti-PD-1 Immune Modulatory Monoclonal Antibody From CureTech Ltd.

November 23, 2014

Yuval Horn will join a panel at the upcoming IBA Annual Conference in Tokyo, Japan (October 2014).

October 21, 2014

Yuval Horn will moderate a panel at the upcoming IBA Annual Conference in Tokyo, Japan (October 2014).

October 21, 2014

Amnon Ovadia (Babylon Software Ltd.) purchases the translation business from Babylon Ltd. (TASE)

September 30, 2014

ANTI CURROPTION REGULATION 2014

August 7, 2014

THE INTERNATIONAL WHO’S WHO OF LIFE SCIENCES LAWYERS 2014

August 6, 2014

BIOLEGIS

August 6, 2014

Vascular Biogenics Ltd. announced the pricing of its initial public offering.

July 1, 2014

V-Gen Ltd.’s shareholders sell all of their shares to Newport Corporation.

July 1, 2014

Adv. Yuval Horn participated in the 2nd Annual IBA World Life Sciences Conference

June 1, 2014

Content discovery business Taboola strikes deal with Yahoo Japan

June 1, 2014

Horn & Co. listed by iam Magazine as one of the top 6 recommended Israeli firms in the field of IP transactions.

June 1, 2014

WE MOVED. Our new offices are located at…

April 1, 2014

Yuval Horn participates in the Who’s Who Legal’s Roundtable: Life Sciences 2014.

March 1, 2014

Yuval Horn will chair the Keynote Panel at the 2nd Annual IBA World Life Sciences Meeting.

February 1, 2014

CollPlant Holdings Ltd. completes a public offering.

December 1, 2013

Horn & Co. assisted the public companies association in outlining a proposed modification to the guidelines for disclosure of biomed companies.

December 1, 2013

BUSINESS ASPECTS OF IP

November 10, 2013

Yuval Horn to co-chair a panel at the upcoming IBA Annual Conference in Boston (October 2013).

September 1, 2013

ANTI CORRUPTION REGULATION 2013

August 6, 2013

Horn & Co. listed by iam Magazine (Intellectual Asset Management) as one of the top 6 recommended Israeli firms in the field of Licensing.

August 1, 2013

Yuval Horn will participate in a panel at the AIPPI conference (November 2013).

August 1, 2013

VIM Technologies Ltd. is acquired by Presstek (Israel) Ltd.

August 1, 2013

Immune Pharmaceuticals Ltd. completes its merger with the US publicly traded company Immune Pharmaceuticals Inc.

August 1, 2013

Yuval Horn to co-chair a panel at the IBA World Life Sciences Conference in Dallas, Texas.

May 1, 2013

Horn & Co. Represents the Israeli Public Companies Organization in its dialogue with the ISA.

May 1, 2013

Yuval Horn noted as one of the 5 worldwide leading practitioners in Life Sciences Transactions.

April 1, 2013

Chambers Global ranks Yuval Horn as a leading Israeli practitioner in M&A: High Tech

March 1, 2013

Yuval Horn nominated as Chairperson of the IBA LifeSciences SubCommittee.

December 1, 2012

Immune Pharmaceuticals Ltd., and EpiCept Corporation entere into a definitive merger agreement.

November 8, 2012

Yuval Horn chairs a panel at the IBA Annual Conference in Dublin, Ireland (October 2012).

October 6, 2012

ANTI CORRUPTION REGULATION 2012

August 6, 2012

THE INTERNATIONAL WHO’S WHO OF LIFE SCIENCES LAWYERS 2013

August 6, 2012

Pfizer, Inc. and Protalix BioTherapeutics, Inc. announce that the FDA approved ELELYSO™.

May 6, 2012

ILS Brokers Ltd.’s shareholders sell all of their shares to Leader Capital Markets Ltd.

May 6, 2012

Protalix BioTherapeutics, Inc. raised over $25 million on AMEX.

February 6, 2012

A merger of Gardia Medical Ltd. with Allium Medical Solutions Ltd.

January 6, 2012

Yuval Horn elected as an expert in Life Sciences by Who’s Who of Life Sciences Lawyers 2012.

November 6, 2011

Vision BI shareholders sell controlling interest to Keyrus, SA.

October 6, 2011

INTELLECTUAL PROPERTY RIGHTS – BIOTECHNOLOGY VERSUS SOFTWARE

October 6, 2011

Completion of a merger of IBI Biomedical Innovations Ltd. with Allium Medical Solutions Ltd.

September 8, 2011

Gefen Biomed Investments Ltd. files Shelf Prospectus with ISA.

August 22, 2011

FUNDING AND OPPORTUNITIES OF LIFE SCIENCE COMPANIES

August 6, 2011

Yuval Horn speaks at a dinner party for the French Delegation to THE ILSI-BIOMED 2011 CONFERENCE

May 6, 2011

FUNDING AND OPPORTUNITIES OF LIFE SCIENCE COMPANIES

May 6, 2011

COMPARING BIOTECHNOLOGY AND SOFTWARE LICENSING AGREEMENTS

May 6, 2011

THE STATE OF THE ISRAELI LIFE SCIENCE

February 6, 2011

COMPARING LIFE SCIENCE AND TECHNOLOGY LICENSES

February 6, 2011

TECHNOLOGY RIGHTS AND DISTRESSED COMPANIES IN ISRAEL

October 6, 2010

THE INTERNATIONAL WHO’S WHO OF LIFE SCIENCES LAWYERS

August 6, 2010

IP CHALLENGES AND OPPORTUNITIES IN ISRAELI BIOTECH

June 14, 2009

COLLABORATIONS AS ALTERNATIVE FINANCING

May 7, 2009